FOR IMMEDIATE RELEASE: December 15, 2015
CONTACT: Gina DiGravio, 617-638-8480, email@example.com
(Boston)–For the first time, CTE has been confirmed as a unique disease that can be definitively diagnosed by neuropathological examination of brain tissue. A consensus panel of expert neuropathologists concluded that CTE has a pathognomonic signature in the brain, an advance that represents a milestone for CTE research and lays the foundation for future studies defining the clinical symptoms, genetic risk factors and therapeutic strategies for CTE.
The neuropathological criteria defining CTE, or the NINDS CTE criteria, which appear in the journal Acta Neuropathologica, had been announced earlier this year at the Foundation of the National Institutes of Health (NIH) board meeting.
CTE is a progressive degenerative disease of the brain found in persons with a history of repetitive brain trauma, including symptomatic concussions as well as asymptomatic sub-concussive hits to the head. The trauma triggers progressive degeneration of the brain tissue, including the build-up of an abnormal protein called tau. These changes in the brain can begin months, years or even decades after the last brain trauma or end of active athletic involvement. The brain degeneration is associated with memory loss, confusion, impaired judgment, impulse control problems, aggression, depression, and, eventually, progressive dementia.
A consensus panel of seven neuropathologists independently reviewed slides from 25 cases of different diseases associated with tau deposits in the brain, completely blinded to all clinical information, including age, sex, clinical symptoms and athletic exposure using provisional diagnostic criteria for CTE developed by Ann McKee, MD, Director of the CTE Program at Boston University and Chief of Neuropathology, VA Boston Healthcare System. The neuropathologists concluded that the criteria distinguished CTE from other tauopathies, including aging and Alzheimer’s disease, and that CTE had a unique pathological signature in the brain.
According to McKee, neuropathologists agreed on the diagnosis of CTE and confirmed the interim standards. “The specific feature considered unique to CTE was the abnormal perivascular accumulation of tau in neurons, astrocytes and cell processes in an irregular pattern at the depths of the cortical sulci,” explained McKee who is corresponding author of the study. “This lesion was not characteristic of any of the other disorders, including Alzheimer’s disease, age-related tauopathy or progressive supranuclear palsy, and has only been found in individuals who were exposed to brain trauma, typically multiple episodes,” she added.
Funding for this study was provided by the National Institute of Neurological Disorders and Stroke (1U01NS086659-01, R01NS078337, R56NS078337, R01NS095252), Department of Defense (W81XWH-13-2-0064, W81XWH-14-1-0399), Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the National Institute of Aging Boston University Alzheimer’s Disease Center (P30AG13846; supplement 0572063345–5), Department of Defense Peer Reviewed Alzheimer’s Research Program (DoD-PRARP #13267017), the National Institute of Aging Boston University Framingham Heart Study (R01AG1649), the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, WWE and the National Football League as well as by grants P50 AG05681 and P01 AG03991 from the National Institute on Aging (NJC).
# # #